| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NeoGenomics, Inc.
$17.37
+1.09 (+6.49%)
D 35Pipeline Score Diagnostics · Commercial
Market Cap
2.23 B
EPS
-0.77
P/E Ratio
-
Value Trade
32.30 M
5.08 %
Week
29.63 %
1 Month
70.46 %
3 Month
70.8 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.68 M
52 Week Range
6.65 - 17.45
% held by Insiders
1.88 %
% held by Institutions
113.65 %
Enterprise Value
2.46 B
Total Shares
128.48 M
Short %
12.6 %
Float Shares
127.59 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeoGenomics, Inc.
114Total events
0Upcoming
21Tier-1 (high impact)
2012 – 2026Coverage
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲FDA ApprovalFDA Decision
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D35
Pipeline Score $183M
Pipeline ValueValuation Signal
1
Drugs Scored0.3x
rNPV / MCap Top 51%
Small Cap (rank 458 of 933)
Percentile RankNeoGenomics, Inc. faces pipeline headwinds (35/100), with $564M risk-adjusted pipeline value, led by AZD2936 in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZD2936 Monoclonal antibody | Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase 2 | NCT05414032 | 14% | $564M | RECRUITING | 102 | - | - | Jul 1, 2028 | ELEVATED_RISK | Feb 25, 2026 |
NEO Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NEO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NEO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-NEO
Aug 26, 2026▲ +6.5%today
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics has announced that its RaDaR ST minimal residual disease (MRD) assay has received expanded coverage under Medicare's MolDX program. This assay is designed for monitoring immunotherapy responses in patients with late-stage solid tumors, potentially improving patient management and treatment outcomes.
Read more →-NEO
Jul 28, 2026▲ +14%on this news
NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics has reported its financial results for the second quarter of 2026, ending on June 30. The announcement was made from Fort Myers, Florida. Specific details regarding revenue, profit, or other financial metrics were not included in the provided text.
Read more →-NEO
Jul 20, 2026NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics has announced a settlement regarding its voluntary disclosure to the Office of Inspector General for Health and Human Services (OIG-HHS). This settlement reflects the company's efforts to address compliance matters proactively. The announcement highlights NeoGenomics' commitment to maintaining regulatory standards.
Read more →-NEO
Jul 9, 2026NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics has launched the PTEN IHC CDx, marking it as the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. FDA specifically for patients with prostate adenocarcinoma. This approval represents a significant step forward in the field of personalized medicine, aiming to enhance treatment strategies for prostate cancer patients.
Read more →-NEO
Jul 7, 2026NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics has announced the date for its second quarter 2026 financial results report, which is scheduled for July 28, 2026. The announcement is part of the company's regular financial reporting cycle. Further details regarding the financial performance will be provided at that time.
Read more →-NEO
Jun 25, 2026▲ +6.4%on this news
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics has appointed Carolyn Starrett to its Board of Directors. This decision is part of the company's ongoing efforts to enhance its leadership team. The appointment aims to bring valuable insights and experience to the board, although specific details regarding her role and contributions were not disclosed.
Read more →-NEO
Jun 17, 2026NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics has announced the pricing of an offering of $275 million in convertible senior notes. This move is part of the company's financial strategy, although specific details about the intended use of proceeds or terms of the notes have not been disclosed.
Read more →-NEO
Jun 15, 2026NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. has announced a proposed offering of $275 million in convertible senior notes due 2032, aimed at qualified institutional buyers. The company may grant purchasers an option to buy an additional $41.25 million in notes as part of the offering, subject to market conditions. Proceeds from the offering will be used for capped call transactions, repaying existing convertible notes, and repurchasing shares of common stock. However, the success of the offering depends on fluctuating market conditions, and there are no guarantees regarding its completion.
Read more →-NEO
May 26, 2026NeoGenomics to Present New Research at ASCO Annual Meeting 2026
NeoGenomics, Inc. announced its participation in the 2026 ASCO Annual Meeting, where it will present eight scientific abstracts focused on advancements in precision oncology and molecular residual disease. The presentations will cover various topics, including genomic profiling and the impact of insurance coverage on next-generation sequencing. The company aims to enhance personalized cancer treatment through innovative diagnostics.
Read more →-NEO
Apr 29, 2026NeoGenomics Reports First Quarter 2026 Results
NeoGenomics reported a strong first quarter for 2026, with total revenue rising 11% year-over-year to $187 million. The company also saw a 14% increase in clinical revenue, driven by a 26% growth in next-generation sequencing (NGS). Additionally, NeoGenomics raised its full-year revenue guidance to between $797 million and $803 million, reflecting confidence in its growth strategy.
Read more →-NEO
Apr 13, 2026NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
NeoGenomics, a leader in oncology diagnostics, will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego. The research emphasizes the importance of combining laboratory testing with clinical data to drive advancements in oncology. CEO Tony Zook highlighted the company's collaborations with biopharma partners, showcasing how these insights can enhance therapy development.
Read more →-NEO
Feb 26, 2026NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics has launched RaDaR ST, a new ctDNA assay for detecting molecular residual disease (MRD) across various solid tumor types. This innovative test aims to provide earlier detection of cancer recurrence, supporting better clinical decisions. The assay is validated through extensive clinical data and is approved by Medicare for initial indications.
Read more →-NEO
Feb 18, 2026▼ -10.3%on this news
NeoGenomics to Participate in Upcoming March 2026 Investor Conferences
NeoGenomics, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company, known for its oncology diagnostic solutions, aims to enhance investor engagement and showcase its innovative services. Live and archived webcasts of the sessions will be available on its Investor Relations website.
Read more →-NEO
Feb 17, 2026NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics reported a strong financial performance for Q4 and full-year 2025, with a 10% increase in revenue to $727 million. The company highlighted significant growth in clinical revenue and successful resolution of patent litigation. However, they also faced a net loss of $108 million for the year, attributed to lower non-clinical revenue and increased operating expenses. Looking ahead, the launch of the RaDaR ST MRD assay is expected to enhance their offerings in the molecular residual disease monitoring market.
Read more →-NEO
Feb 12, 2026NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics has launched PanTracer Pro, a new testing solution designed to assist clinicians in making informed decisions for patients with advanced-stage solid tumors. This integrated approach aims to streamline the diagnostic process by providing earlier biomarker insights and reducing uncertainty in complex cases. The test offers a turnaround time of 8-10 days, facilitating timely treatment planning.
Read more →-NEO
Jan 27, 2026NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. will announce its fourth quarter and full year 2025 financial results on February 17, 2026. The results will be shared prior to the U.S. market opening, followed by a conference call at 8:30 a.m. ET. The company provides a comprehensive range of oncology diagnostic solutions.
Read more →-NEO
Jan 5, 2026NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management is set to present and engage in a Q&A session on January 13. This event provides a platform for NeoGenomics to highlight its oncology diagnostic solutions and connect with investors.
Read more →-NEO
Dec 30, 2025NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
NeoGenomics has appointed John P. Kenny to its Board of Directors, filling the vacancy left by Alison Hannah. Kenny, a seasoned professional with over 30 years in diagnostics, is expected to leverage his experience to drive growth in cancer testing. His previous roles include leadership positions at Meridian Bioscience and Siemens Healthcare.
Read more →-NEO
Dec 11, 2025NeoGenomics to Present New ctDNA Research at SABCS 2025
NeoGenomics, Inc. will present new findings from its RaDaR 1.0 assay at the 2025 San Antonio Breast Cancer Symposium. The data, derived from the SURVIVE HERoes Phase III trial and the CLEVER study, focus on assessing molecular residual disease and recurrence risk in early breast cancer. The findings aim to enhance the integration of ctDNA testing into routine oncology care.
Read more →-NEO
Jun 24, 2025NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
NeoGenomics has appointed Dr. Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green, who is currently a Senior Vice President at Merck overseeing Global Clinical Development in oncology, is expected to leverage her extensive experience in oncology and corporate strategy to help drive the company's growth. The Board expresses enthusiasm about Dr. Green's addition, emphasizing her capability to innovate within the precision oncology market. This appointment marks a strategic move as NeoGenomics positions itself for future development and investment in oncology diagnostics.
Read more →-NEO
Apr 14, 2022Key 2021 Financial Highlights and Accomplishm nts Increased consolidated venue by 9% y r-over-year. Clinical Services revenue in ased 6 to $404 million. Grew Pharma Services revenue 2 % to $80 million and increased backl
Key 2021 Financial Highlights and Accomplishm nts Increased consolidated venue by 9% y r-over-year. Clinical Services revenue in ased 6 to $404 million. Grew Pharma Services revenue 2 % to $80 million and increased backlog to $267 million. Strengthened financial position with $74
Read more →-NEO
Mar 28, 2022NeoGenomics Announces CEO Departure and Initiates CEO Search Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance Ft. Myers, Florida
NeoGenomics Announces CEO Departure and Initiates CEO Search Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance Ft. Myers, Florida March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the Compan
Read more →-NEO
Jun 18, 2021NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform - Acquisition establishes NeoGenomics as a technology leader in the minimal residual d
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform -Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market Ft. Myers, Florida - June 18, 2
Read more →-NEO
May 5, 2021NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform - Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing ma
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform -Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market -NeoGenomics exercises option struck in May 2020 to p
Read more →-NEO
Apr 15, 2021Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming
Key 2020 Financial Highlights and Accomplishments OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we are becoming the world's leading cancer testing and information company.
Read more →-NEO
Mar 24, 2021NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Ft. Myers, Florida
NeoGenomics Agrees to Acquire Trapelo Health Clinical Decision Support to Enable Precision Oncology Ft. Myers, Florida - March 24, 2021 - NeoGenomics, Inc. (NASDAQ NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services
Read more →-NEO
Jan 6, 2021NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Fort Myers, Florida (
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Fort Myers, Florida (January 6, 2021) - NeoGenomics, Inc. (NASDAQ NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract rese
Read more →-NEO
Apr 29, 2020only by means of the prospectus for the notes offering and the prospectus supplement and the accompanying prospectus for the common stock offering and short sale. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Fort Myers, Florida (April 30, 2020) - NeoGenomics, Inc. (NASDAQ NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced the pricing of co
Read more →-NEO
Jun 28, 2019Genoptix business and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on
NeoGenomics Announces New $250 Million Credit Agreement Ft. Myers, Florida - June 27, 2019 - NeoGenomics, Inc. (NASDAQ NEO), a leading provider of cancer-focused genetic testing services, today announced that the company has entered into a new $250 million five-year Senior Secur
Read more →-NEO
May 21, 2019NeoGenomics Announces Pricing on Public Offering of Common Stock
NeoGenomics Announces Pricing on Public Offering of Common Stock Ft. Myers, Florida - May 21, 2019 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of its underwritten public offering of 7,000,000 share
Read more →-NEO
May 2, 2019neogenomicsinvestor INVESTOR PRESENTATION April 2019 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational p
INVESTOR PRESENTATION April 2019 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an o
Read more →-NEO
Dec 12, 2018NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder Ft. Myers, Florida
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder Ft. Myers, Florida - December 12, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten sec
Read more →-NEO
Dec 11, 2018NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder Ft. Myers, Florida
NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder Ft. Myers, Florida - December 11, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that GE Medical Systems Information Technolog
Read more →-NEO
Dec 10, 2018HISTORICAL CONSOLIDATED FINANCIAL INFORMATION INDEPENDENT AUDITORS' REPORT To the Board of Directors and Members of Genesis Acquisition Holdings Corp. and Subsidiaries We have audited the accompanying consolidated balanc
HISTORICAL CONSOLIDATED FINANCIAL INFORMATION INDEPENDENT AUDITORS' REPORT To the Board of Directors and Members of Genesis Acquisition Holdings Corp. and Subsidiaries We have audited the accompanying consolidated balance sheet of Genesis Acquisition Holdings Corp. and subsid
Read more →-NEO
Dec 10, 2018NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer Ft. Myers, Florida
NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer Ft. Myers, Florida - December 10, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the appointment of Lawrence M. Weiss, M.D. as Chief Sci
Read more →-NEO
Aug 6, 2018NeoGenomics Announces Proposed Public Offering of Common Stock Ft. Myers, Florida
NeoGenomics Announces Proposed Public Offering of Common Stock Ft. Myers, Florida - August 6, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of approxima
Read more →-NEO
Jun 1, 2018PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions Expanding global oncology testing for clinical trials WILMINGTON, N.C. (
lives by improving patient care through communication, accuracy, reliability and efficiency. That commitment aligns closely with PPD's mission and purpose to help its customers deliver life-changing therapies that improve health." As a premier cancer diagnostics and pharma servic
Read more →-NEO
May 25, 2018Supplemental Information Impact of ASU 606 Adoption (in thousands) For the Year Ended
Supplemental Information Impact of ASU 606 Adoption For the Year Ended December 31, 2017 (Adjusted) 2016 (Adjusted) NET REVENUE Clinical testing $ 213,097 $ 210,159 Pharma Services 25,748 21,648 Total Revenue $ 238,845 $ 231,807 Gross Margin $ 100,551 $ 98,103
Read more →-NEO
Feb 21, 2018NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017 Gross Margin Improveme
NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017 Gross Margin Improvement to 48.9% Ft. Myers, Florida - February 21, 2018 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of canc
Read more →-NEO
Oct 25, 2017NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017 37% Increase in Pharma Servi
NeoGenomics Reports Revenue of $63.1 Million on 17% Volume Growth and 11% Reduction in Average Cost per Test in the Third Quarter of 2017 37% Increase in Pharma Services Revenue Ft. Myers, Florida - October 25, 2017 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cance
Read more →-NEO
Oct 12, 2017NEOGENOMICS, INC PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 Guidance Fort Myers, FL
NeoGenomics Announces Preliminary Quarter 3 Results, Financial Impacts of Hurricanes and Summary Quarter 4 Guidance Fort Myers, FL - October 12, 2017 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it expect
Read more →-NEO
Jul 25, 2017NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 Significant Improvem
NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 Significant Improvement in Gross Margin Ft. Myers, Florida - July 25, 2017 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of
Read more →-NEO
May 25, 2017Meeting Agenda - May 25th 8:00 - 8:30am Annual Shareholders Meeting Analyst/Investor Day Presentations 8:30 - 9:15am CEO Review 9:15 - 10:00am Pathologist Perspective 10:00 - 10:15am Break 10:15 - 11:00am Pharma Services
Annual Meeting and Investor Day May 25, 2017 Exhibit 99.1 Meeting Agenda - May 25th 8:00 - 8:30am Annual Shareholders Meeting Analyst/Investor Day Presentations 8:30 - 9:15am CEO Review 9:15 - 10:00am Pathologist Perspective 10:00 - 10:15am Break 10:15 - 11:00am Pharma Services
Read more →-NEO
Apr 26, 2017NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 Integration of Southern California Facilities and Clarie
NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 Integration of Southern California Facilities and Clarient Clients Now Complete Ft. Myers, Florida - April 26, 2017 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provide
Read more →-NEO
Feb 22, 2017Transcript of NeoGenomics, Inc. Fourth Quarter and Full Year 2016 Financial Results
Fourth Quarter and Full Year 2016 Financial Results Doug VanOort - Chairman and CEO George Cardoza - Senior Vice President and Chief Financial Officer Steve Jones - Executive Vice President Bill Bonello - Craig-Hallum Amanda Murphy - William Blair Drew Jones - Stephens Pau
Read more →-NEO
Feb 22, 2017NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 Migration of all Clarient Clients to
NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 Migration of all Clarient Clients to NeoGenomics Lab Information System Now Complete Ft. Myers, Florida - February 22, 2017 - NeoGenomics, Inc. (NAS
Read more →-NEO
Dec 22, 2016NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Closes $150 Million Senior Credit Facility Ft. Myers, Florida
NeoGenomics Closes $150 Million Senior Credit Facility Ft. Myers, Florida December 22, 2016 NeoGenomics, Inc. (NASDAQ: NEO) (the Company ) announced today that it has closed on a new five year, $150 million senior secured credit facility, which includes a $75 million revolving
Read more →-NEO
Oct 26, 2016NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 Acceleration in Cash Flow
NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 Acceleration in Cash Flow Creating Additional Financial Flexibility Ft. Myers, Florida - October 26, 2016 - NeoGenomics, Inc. (NASDAQ: NE
Read more →-NEO
Jul 26, 2016NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 Integration of Clarient acquisition on track
NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 Integration of Clarient acquisition on track and progressing well. Ft. Myers, Florida - July 26, 2016 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider o
Read more →-NEO
Jun 8, 2016Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act
Annual Shareholder Meeting June 7, 2016 NASDAQ: NEO Exhibit 99.1 Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchan
Read more →-NEO
Apr 28, 2016NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands) For the three months ended March 31, CASH FLOWS FROM OPERATING ACTIVITIES 2016 2015 Net income (loss) $ 155 $ (761 ) Adjs. to re
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains Company Increases Full Year 2016 Revenue, EPS & Adjusted EBITDA Guidance Ft. Myers, Florida - April 27, 2016 - NeoG
Read more →-NEO
Mar 1, 2016NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands) For the year ended
NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains Integration of Clarient on Track and Proceeding at a Rapid Pace. Ft. Myers, Florida - March 1, 2016 - NeoGenomics, Inc. (NASDAQ: NEO),
Read more →-NEO
Oct 28, 2015NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services Ft. Myers, Florida
NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services Ft. Myers, Florida - October 28, 2015 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an amended Strategic Alliance Agreemen
Read more →-NEO
Oct 21, 2015NEOGENOMICS, INC PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics signs Definitive Agreement to acquire Clarient, Inc. GE Healthcare retains significant stake in NeoGenomics and Parties agree to collaborate on Bioinformat
NeoGenomics signs Definitive Agreement to acquire Clarient, Inc. GE Healthcare retains significant stake in NeoGenomics and Parties agree to collaborate on Bioinformatics Initiative Fort Myers, FL - October 21, 2015 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cance
Read more →-NEO
Jul 23, 2015NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 18% Revenue Growth and Strong Gains in Adjusted EBITDA Significant Expansion in Gross Margin as Costs per Test Fall to Record Levels Ft. Myers, Fl
NeoGenomics Reports 18% Revenue Growth and Strong Gains in Adjusted Expansion in Gross Margin as Costs per Test Fall to Record Levels Ft. Myers, Florida July 23, 2015 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today report
Read more →-NEO
Apr 28, 2015NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 27% Revenue Growth Driven by Strong Volume Gains and PathLogic Acquisition Ft. Myers, Florida
NeoGenomics Reports 27% Revenue Growth Driven by Strong Volume Gains and PathLogic Acquisition Ft. Myers, Florida April 28, 2015 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2
Read more →-NEO
Feb 24, 2015NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Revenue of $25.0 Million, Adjusted EBITDA of $2.8 MM and Net Income of $0.02 per Share for the Fourth Quarter 2014 Company s Commitment to
NeoGenomics Reports Record Revenue of $25.0 Million, Adjusted EBITDA of $2.8 MM and Net Income of $0.02 per Share for the Company s Commitment to Fast-paced Innovation Continues to Drive Growth. Ft. Myers, Florida February 24, 2015 - NeoGenomics, Inc. (NASDAQ: NEO), a leading p
Read more →-NEO
Jan 22, 2015NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014 Company Now Projecting 36% Year-Over-Year Revenue G
NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014 Company Now Projecting 36% Year-Over-Year Revenue Growth in Quarter 4 Ft. Myers, Florida January 22, 2015 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of ca
Read more →-NEO
Oct 30, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014 Company Raises Full-Year Reven
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter Company Raises Full-Year Revenue Guidance to $85.0 to $86.5 Million Ft. Myers, Florida October 30, 2014 - NeoGenomics, Inc. (NASDAQ: NEO), a leading p
Read more →-NEO
Oct 14, 2014CHARTER OF THE COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS OF NEOGENOMICS, INC. (the Corporation ) Adopted
CHARTER OF THE COMPLIANCE COMMITTEE Adopted October 14, 2014 The Compliance Committee assists the board of directors of the Corporation (the Board ) with overseeing the Corporation s activities in the areas of compliance with laws and regulations applicable to its business. T
Read more →-NEO
Aug 22, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters Over-Allotment Option Ft. Myers, Florida
NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters Over-Allotment Option Ft. Myers, Florida August 22, 2014 NeoGenomics, Inc. (NASDAQ: NEO) (the Company ), a leading provider of cancer-focused genetic testing services, today announced t
Read more →-NEO
Aug 15, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Announces Pricing of $32.2 Million Public Offering Seven Million Share Offering at $4.60 per Share Ft. Myers, Florida
NeoGenomics Announces Pricing of $32.2 Million Public Offering Seven Million Share Offering at $4.60 per Share Ft. Myers, Florida August 15, 2014 - NeoGenomics, Inc. (NASDAQ: NEO) (the Company ), a leading provider of cancer-focused genetic testing services, today announced th
Read more →-NEO
Jul 17, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014 Company Raises Full-Year Revenu
NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Company Raises Full-Year Revenue Guidance to $83 - $86 Million Ft. Myers, Florida July 17, 2014 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of can
Read more →-NEO
Jul 8, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Completes Acquisition of Path Logic Adds Specialized Anatomic Pathology Services Fort Myers, Florida
NeoGenomics Completes Acquisition of Path Logic Adds Specialized Anatomic Pathology Services Fort Myers, Florida July 08, 2014 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has acquired Path Labs, LLC
Read more →-NEO
Apr 23, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter Company Increases Revenue and EPS Guidance for the Full-Year Ft
NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter Company Increases Revenue and EPS Guidance for the Full-Year Ft. Myers, Florida April 23, 2014 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic
Read more →-NEO
Feb 19, 2014NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013 Company Set to Laun
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Company Set to Launch Next Generation Sequencing Services in March 2014 Ft. Myers, Florida - February 19, 2014 - NeoGenomics, Inc. (NASDAQ: NEO), a lea
Read more →-NEO
Nov 18, 2013Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials Alliance provides clients wi
Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials Alliance provides clients with seamless global specialty testing services critical to
Read more →-NEO
Oct 23, 2013NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013 Ft. Myers, Florida
NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Ft. Myers, Florida October 23, 2013 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its resul
Read more →-NEO
Jul 31, 2013NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013 Ft. Myers, Florida
NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter Ft. Myers, Florida - July 31, 2013 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reporte
Read more →-NEO
May 9, 2013MISSION: To improve patient care through exceptional cancer genetic diagnostic services VISION: By delivering uncompromising quality, exceptional service and innovative solutions, we are becoming America s premier cancer
To improve patient care through exceptional cancer genetic diagnostic services By delivering uncompromising quality, exceptional service solutions, we are becoming America s premier cancer testing laboratory. Accountability Teamwork Employee, Customer & Results Focused (in
Read more →-NEO
Apr 25, 2013NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter Successfully completes $10
NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter Successfully completes $10 Million Equity Raise Ft. Myers, Florida April 25, 2013 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of
Read more →-NEO
Feb 28, 2013NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Announces Pricing of $9.5 Million Public Offering 3.15 Million Share Offering at $3.00 per Share Ft. Myers, Florida
NeoGenomics Announces Pricing of $9.5 Million Public Offering 3.15 Million Share Offering at $3.00 per Share Ft. Myers, Florida February 28, 2013 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has priced
Read more →-NEO
Feb 14, 2013NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012 Provides Financial Outlook for 2013 Ft. Myers, Florida
NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012 Provides Financial Outlook for 2013 Ft. Myers, Florida - February 14, 2013 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing ser
Read more →-NEO
Dec 6, 2012NEOGENOMICS, INC. PRESS RELEASE FOR IMMEDIATE RELEASE NeoGenomics Announces NASDAQ Capital Market Listing Ft. Myers, Florida
NeoGenomics Announces NASDAQ Capital Market Listing Ft. Myers, Florida December 6, 2012 NeoGenomics, Inc. (OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today that its common stock has been approved for listing on the NASDAQ Capital Mar
Read more →Competitive Position
How NEO ranks across every disease it competes inCompetitive Position is a premium feature
See how NEO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial